Cash and cash equivalents are anticipated to be sufficient to fund operations as currently planned into 2027.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- YMAB Upcoming Earnings Report: What to Expect?
- Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
- Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
- Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
- Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue